Related references
Note: Only part of the references are listed.A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
Joachim Tillner et al.
DIABETES OBESITY & METABOLISM (2019)
Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type2 Diabetes
Jia Ying Cheang et al.
CHEMMEDCHEM (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes
Anders Gummesson et al.
DIABETES OBESITY & METABOLISM (2017)
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
Heidi Storgaard et al.
DIABETES OBESITY & METABOLISM (2017)
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
V. Salem et al.
DIABETES OBESITY & METABOLISM (2016)
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Matthias H. Tschoep et al.
CELL METABOLISM (2016)
Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults
Hollie A. Raynor et al.
JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS (2016)
Assessing the effect of weight and weight loss in obese persons with type 2 diabetes
Bradley Curtis et al.
Diabetes Metabolic Syndrome and Obesity-Targets and Therapy (2016)
A systematic review of the safety of incretin-based therapies in type 2 diabetes
Marc Evans et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2016)
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
Kira B. Harris et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2015)
Long-term Drug Treatment for Obesity A Systematic and Clinical Review
Susan Z. Yanovski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Impact of Adherence and Weight Loss on Glycemic Control in Patients with Type 2 Diabetes: Cohort Analyses of Integrated Medical Record, Pharmacy Claims, and Patient-Reported Data
Carrie McAdam-Marx et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2014)
Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
Tricia M. Tan et al.
DIABETES (2013)
Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories A Systematic Review and Meta-analysis
Katherine M. Flegal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
Matteo Monami et al.
EXPERIMENTAL DIABETES RESEARCH (2012)
Metabolic insights from cutting the gut
Keval Chandarana et al.
NATURE MEDICINE (2012)
Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
Patrick M. O'Neil et al.
OBESITY (2012)
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability
Alan J. Garber
DIABETES CARE (2011)
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Rena R. Wing et al.
DIABETES CARE (2011)
The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review
Vanita R. Aroda et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2011)
Benefits of moderate weight loss in patients with type 2 diabetes
Ken Fujioka
DIABETES OBESITY & METABOLISM (2010)
Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes
Blandine Laferrere et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
Carel W. le Roux et al.
ANNALS OF SURGERY (2007)
Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes
Blandine Laferrere et al.
DIABETES CARE (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
Effect of weight loss with lifestyle intervention on risk of diabetes
Richard F. Hamman et al.
DIABETES CARE (2006)
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin
C Berne
DIABETIC MEDICINE (2005)
Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: A meta-analysis
SL Norris et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials
R Padwal et al.
INTERNATIONAL JOURNAL OF OBESITY (2003)
Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults
HE Resnick et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2000)
Obesity and insulin resistance
BB Kahn et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
